INTEGRATED MEDICINE AT MERRIMACK.
Three pillars guide our approach to overcoming cancer’s complexity.
Biomarkers help to select a therapy specific to an individual’s cancer
Identifying predictive biomarkers. While all cancers share certain characteristics, each is ultimately distinct in its composition, molecular signature, and anatomic location. Sensitivity to therapeutics is driven by all of these factors. Developing tools to select a therapy specific to an individual’s cancer may help determine their best course of treatment. Merrimack is committed to changing the landscape of cancer treatment by developing our investigational therapeutics with companion diagnostics, an approach intended to better identify patients most likely to respond to a specific therapy.
Antibodies target pathways of resistance
Targeting pathways of resistance. Merrimack’s human antibody engineering platform provides us with the ability to create monoclonal (MM-121 seribantumab), bispecific (MM-141 istiratumab), and oligoclonal (MM-151) antibodies targeting the complex signaling pathways that drive cancer. These molecules are designed to inhibit specific nodes responsible for tumor growth and survival, or to address inherent drug resistance by simultaneously targeting redundant signaling pathways.
Our nanoliposomes reengineer the delivery of chemotherapies to cancer cells
Rethinking approaches to chemotherapy delivery. Our nanoliposome platform enables us to create both passively targeted and actively targeted liposomes, each containing different chemotherapeutic agents.
We believe comprehensive regimens are the future of cancer care. See where we stand today.
“A deeper understanding of the mechanisms of cancer resistance, more precise diagnostic tools, and the development of medicines to treat these changes are the real breakthroughs we need to cure cancer.”
— Patricia M. LoRusso, D.O.,
Clinical Trial Specialist in Oncology